The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2022
Filed:
Oct. 05, 2018
Applicant:
Prothena Biosciences Limited, Dublin, IE;
Inventors:
Joshua Reginald Salmans, South San Francisco, CA (US);
Svetlana Alexander, Sunnyvale, CA (US);
Robin Barbour, Walnut Creek, CA (US);
Jeffrey N. Higaki, San Mateo, CA (US);
Tarlochan S. Nijjar, Orinda, CA (US);
Assignee:
Other;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.